Can a New Alzheimer’s Drug Give Families More ‘Golden Hours’?

Can slowing Alzheimer’s create more precious family moments? New research suggests it may help.

For families living with Alzheimer’s disease, every clear conversation, shared smile, or familiar memory can feel priceless. Now, a growing number of patients in Hong Kong are seeking a new treatment that may help preserve those precious moments—often described by doctors and caregivers as “golden hours” of meaningful connection with loved ones.

The treatment, lecanemab, is one of the first disease-modifying therapies for early Alzheimer’s disease. Unlike medications that mainly manage symptoms, lecanemab targets amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease, with the goal of slowing the progression of cognitive decline rather than reversing it. Early treatment offers patients more time to remain independent and engage with family before the disease advances.

More ‘Golden Hours,’ Not a Cure for Alzheimer’s

Doctors emphasize that the treatment is not a cure for Alzheimer’s disease. Instead, its greatest benefit lies in slowing the disease during its earliest stages, allowing patients to maintain their memory, communication, and daily functioning for longer.

Neurologists say that even a modest delay in cognitive decline can have a profound impact on quality of life. Extra months—or even years—of recognizing family members, participating in conversations, or enjoying everyday routines can make a meaningful difference for both patients and caregivers.

This is why many specialists describe the treatment as helping patients gain more “golden hours”—valuable time when they can continue to share experiences with those closest to them.

Hope Comes With Careful Screening for Alzheimer’s Disease

Not everyone with Alzheimer’s disease is eligible for the therapy. Lecanemab is intended for people with early Alzheimer’s disease or mild cognitive impairment caused by Alzheimer’s pathology. Before treatment begins, patients typically undergo brain imaging and biomarker testing to confirm the presence of amyloid deposits, ensuring the medication is used in those most likely to benefit.

Doctors also closely monitor patients throughout treatment because the medication can cause amyloid-related imaging abnormalities (ARIA)—brain swelling or small areas of bleeding that are usually detected through regular MRI scans. Most cases are mild, but careful monitoring is considered essential.

Research Supports Slower Cognitive Decline

Clinical evidence supporting lecanemab comes from the Phase III CLARITY AD trial, published in the New England Journal of Medicine.

The international study found that patients receiving lecanemab experienced a 27% slower rate of cognitive decline over 18 months compared with those given a placebo. () Researchers also observed significant reductions in amyloid plaque levels in the brain, suggesting the drug addresses one of the biological processes associated with Alzheimer’s disease rather than simply easing symptoms.

Experts caution that while the treatment slows disease progression, it does not restore lost memory or halt Alzheimer’s completely. Even so, delaying decline may allow patients to remain independent longer and reduce some of the emotional and caregiving burden faced by families.

A Shift in Alzheimer’s Care

For decades, Alzheimer’s treatment focused largely on managing symptoms after memory loss had become noticeable. The arrival of disease-modifying therapies marks a significant shift toward earlier diagnosis and intervention.

This change is encouraging more people experiencing early memory problems to seek medical evaluation sooner, when treatments have the greatest chance of providing benefit. Specialists say increased awareness, earlier screening, and advances in biomarker testing are becoming increasingly important as new therapies emerge.

Giving Families More Time Together

For many families, the value of treatment cannot be measured only by clinical scores or brain scans. Instead, it lies in preserving the everyday moments that Alzheimer’s disease gradually takes away—remembering birthdays, recognizing grandchildren, enjoying a shared meal, or simply having a meaningful conversation.

While scientists continue searching for a cure, therapies such as lecanemab are offering something many families consider equally precious: more quality time together, helping patients hold on to their independence and relationships for as long as possible.

Research suggests that even slowing the progression of Alzheimer’s disease can translate into more meaningful experiences and improved quality of life for patients and those who care for them.

References:

1. Lecanemab in Early Alzheimer’s Disease – (https://www.nejm.org/doi/full/10.1056/NEJMoa2212948)

Source-Medindia